Medigene AG (LON:0QGJ)
London · Delayed Price · Currency is GBP · Price in EUR 0.1120
-0.0730 (-39.46%)
Inactive · Last trade price on Apr 29, 2025
Medigene AG Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2014 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2014 - 2018 |
Operating Revenue | 7.45 | 6.03 | 31.25 | 10.46 | 8 | 10.51 | Upgrade |
| 7.45 | 6.03 | 31.25 | 10.46 | 8 | 10.51 | Upgrade | |
Revenue Growth (YoY) | -17.51% | -80.69% | 198.64% | 30.75% | -23.87% | 38.74% | Upgrade |
Cost of Revenue | 1.49 | 1.64 | 1.98 | 1.36 | 1.29 | 0.38 | Upgrade |
Gross Profit | 5.95 | 4.39 | 29.26 | 9.1 | 6.71 | 10.13 | Upgrade |
Selling, General & Admin | 9.06 | 9.34 | 9.89 | 6.84 | 8.56 | 7.79 | Upgrade |
Research & Development | 12.65 | 11.55 | 8.1 | 11.27 | 22.26 | 22.62 | Upgrade |
Other Operating Expenses | -0.34 | -0.34 | -0.43 | -0.68 | 3.09 | -0.12 | Upgrade |
Operating Expenses | 21.37 | 20.54 | 17.56 | 17.42 | 33.91 | 30.29 | Upgrade |
Operating Income | -15.42 | -16.15 | 11.71 | -8.32 | -27.2 | -20.16 | Upgrade |
Interest Expense | -0.54 | -0.54 | -0.63 | -0.34 | -0.4 | -0.45 | Upgrade |
Interest & Investment Income | 0.24 | 0.14 | 0.03 | 0.02 | 0.06 | 0.16 | Upgrade |
Currency Exchange Gain (Loss) | 0.09 | -0.03 | -0.02 | -0.01 | 0.05 | -0.07 | Upgrade |
Other Non Operating Income (Expenses) | 0.01 | -0 | -0.03 | - | -0 | - | Upgrade |
EBT Excluding Unusual Items | -15.62 | -16.59 | 11.06 | -8.66 | -27.48 | -20.52 | Upgrade |
Impairment of Goodwill | - | - | - | - | -2.21 | - | Upgrade |
Gain (Loss) on Sale of Assets | - | - | -0.03 | -0.16 | 0.72 | - | Upgrade |
Asset Writedown | - | - | -20.4 | -1.53 | - | - | Upgrade |
Other Unusual Items | - | - | - | 0.06 | 0.58 | 0.6 | Upgrade |
Pretax Income | -15.62 | -16.59 | -9.37 | -10.28 | -28.4 | -19.92 | Upgrade |
Income Tax Expense | 0.31 | -0.42 | -1.04 | -0.3 | 0.47 | 0.04 | Upgrade |
Net Income | -15.93 | -16.18 | -8.33 | -9.98 | -28.88 | -19.96 | Upgrade |
Net Income to Common | -15.93 | -16.18 | -8.33 | -9.98 | -28.88 | -19.96 | Upgrade |
Shares Outstanding (Basic) | 13 | 12 | 12 | 12 | 12 | 12 | Upgrade |
Shares Outstanding (Diluted) | 13 | 12 | 12 | 12 | 12 | 12 | Upgrade |
Shares Change (YoY) | 2.65% | - | - | - | 0.01% | 3.77% | Upgrade |
EPS (Basic) | -1.26 | -1.32 | -0.68 | -0.81 | -2.35 | -1.63 | Upgrade |
EPS (Diluted) | -1.26 | -1.32 | -0.68 | -0.81 | -2.35 | -1.63 | Upgrade |
Free Cash Flow | -14.79 | -15.78 | 11.02 | -10.88 | -25.27 | -17.85 | Upgrade |
Free Cash Flow Per Share | -1.17 | -1.28 | 0.90 | -0.89 | -2.06 | -1.45 | Upgrade |
Gross Margin | 79.94% | 72.77% | 93.65% | 87.00% | 83.85% | 96.36% | Upgrade |
Operating Margin | -207.04% | -267.63% | 37.46% | -79.50% | -339.87% | -191.81% | Upgrade |
Profit Margin | -213.98% | -268.10% | -26.66% | -95.41% | -360.85% | -189.91% | Upgrade |
Free Cash Flow Margin | -198.68% | -261.57% | 35.27% | -103.98% | -315.80% | -169.83% | Upgrade |
EBITDA | -14.78 | -15.55 | 32.79 | -5.74 | -23.82 | -18.73 | Upgrade |
EBITDA Margin | -198.51% | -257.64% | 104.95% | -54.88% | -297.70% | -178.17% | Upgrade |
D&A For EBITDA | 0.64 | 0.6 | 21.09 | 2.58 | 3.37 | 1.43 | Upgrade |
EBIT | -15.42 | -16.15 | 11.71 | -8.32 | -27.2 | -20.16 | Upgrade |
EBIT Margin | -207.04% | -267.63% | 37.46% | -79.50% | - | -191.81% | Upgrade |
Revenue as Reported | - | - | - | - | - | 10.63 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.